Inozyme Pharma, Inc.
TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
Last updated:
Abstract:
The present disclosure provides, among other things, vectors for expression of ENPP1 or ENPP3 in vivo and methods for the treatment of diseases of calcification and ossification in a subject.
Status:
Application
Type:
Utility
Filling date:
17 Feb 2021
Issue date:
24 Jun 2021